/
/
/

Accent Microcell Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-21%21%32%
-56%53%33%
---170%
22%23%22%19%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
ACCENTMIC-SM
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr
675₹1608 Cr36.67—20.22₹44 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Miscellaneous Expenses not written off
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
——————
₹24 Cr₹21 Cr₹21 Cr₹13 Cr₹13 Cr₹4 Cr
₹251 Cr₹174 Cr₹143 Cr₹37 Cr₹19 Cr₹22 Cr
₹251 Cr₹174 Cr₹143 Cr₹37 Cr₹19 Cr₹22 Cr
₹275 Cr₹195 Cr₹164 Cr₹50 Cr₹32 Cr₹27 Cr
₹34 L₹86 L₹1 Cr₹2 Cr₹3 Cr₹4 Cr
₹0₹0₹2 L₹3 Cr₹4 Cr₹14 Cr
-₹13 L₹89 L₹86 L₹89 L₹1 Cr₹1 Cr
₹2 Cr₹1 Cr₹79 L₹23 L₹42 L₹25 L
₹3 Cr₹3 Cr₹3 Cr₹7 Cr₹9 Cr₹19 Cr
——————
₹20 Cr₹18 Cr₹19 Cr₹35 Cr₹30 Cr₹18 Cr
₹20 Cr₹11 Cr₹8 Cr₹4 Cr₹9 Cr₹6 Cr
₹0₹0₹10 Cr₹15 Cr₹14 Cr₹10 Cr
₹17 Cr₹23 Cr₹10 Cr₹3 Cr₹44 L₹37 L
₹56 Cr₹52 Cr₹46 Cr₹56 Cr₹54 Cr₹35 Cr
₹334 Cr₹250 Cr₹213 Cr₹113 Cr₹95 Cr₹81 Cr
₹20 Cr₹5 Cr₹4 Cr₹0₹0₹0
₹88 L₹2 Cr₹13 Cr₹23 Cr₹24 Cr₹31 Cr
——————
₹94 Cr₹89 Cr₹66 Cr₹64 Cr₹59 Cr₹55 Cr
₹41 Cr₹41 Cr₹37 Cr₹32 Cr₹28 Cr₹24 Cr
₹53 Cr₹48 Cr₹29 Cr₹31 Cr₹30 Cr₹30 Cr
₹102 Cr₹13 Cr₹2 Cr₹0₹0₹0
₹0₹0₹0₹15,000₹0₹0
₹0₹0₹0₹15,000₹0₹0
₹11 Cr₹13 Cr₹11 Cr₹2 Cr₹57 L₹56 L
₹46 L₹4 L₹0₹0₹0₹0
₹167 Cr₹74 Cr₹41 Cr₹33 Cr₹31 Cr₹31 Cr
——————
₹32 Cr₹34 Cr₹33 Cr₹42 Cr₹40 Cr₹32 Cr
₹91 Cr₹65 Cr₹54 Cr₹30 Cr₹17 Cr₹13 Cr
₹20 Cr₹51 Cr₹72 Cr₹2 Cr₹3 Cr₹1 Cr
₹4 Cr₹3 Cr₹2 Cr₹3 Cr₹4 Cr₹3 Cr
₹20 Cr₹23 Cr₹10 Cr₹3 Cr₹49 L₹1 Cr
₹168 Cr₹176 Cr₹172 Cr₹80 Cr₹64 Cr₹50 Cr
₹111 Cr₹124 Cr₹126 Cr₹24 Cr₹10 Cr₹15 Cr
₹0₹0₹0₹6 L₹0₹0
₹334 Cr₹250 Cr₹213 Cr₹113 Cr₹95 Cr₹81 Cr
₹115₹93₹78₹39₹25₹62
₹115₹93₹78₹39₹8₹21

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
₹58 Cr₹44 Cr₹37 Cr₹15 Cr₹8 Cr₹6 Cr
₹4 Cr₹73 L₹6 Cr₹6 Cr₹7 Cr₹3 Cr
-₹30 Cr-₹9 Cr-₹25 Cr-₹11 Cr₹2 Cr-₹3 Cr
₹32 Cr₹36 Cr₹18 Cr₹10 Cr₹17 Cr₹6 Cr
₹19 Cr₹25 Cr₹11 Cr₹8 Cr₹15 Cr₹5 Cr
-₹49 Cr-₹9 Cr-₹82 Cr-₹4 Cr-₹4 Cr-₹6 Cr
₹36 Cr-₹14 Cr₹72 Cr-₹4 Cr-₹10 Cr-₹2 Cr
₹6 Cr₹2 Cr₹1 Cr-₹79 L₹90 L-₹3 Cr
₹4 Cr₹2 Cr₹31 L₹1 Cr₹20 L₹4 Cr
₹9 Cr₹4 Cr₹2 Cr₹31 L₹1 Cr₹20 L

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)665.00
Volume (₹)83,000.00
High (₹)688.50
Upper Circuit804.40
Low (₹)665.00
Lower Circuit536.30
Prev Close670.35
52W High (₹)731.70
Price670.00
52W Low (₹)238.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)1608.10 Cr
Div. Yield (%)0.15
PE Ratio36.67
Debt to Equity0.00
Price to Book3.09
Book Value114.84
EPS (TTM)18.28
Face Value10.00
ROE (%)18.65

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
ACCENTMIC-SMNSE
LTP
1W Low
1W High
Market cap (₹)
1852+14.7 (0.80%)
1832.20
1891.50
4,47,476Cr
9634+259 (2.76%)
9312.50
9740
2,54,764Cr
4937+97 (2.00%)
4848.50
5010
1,89,423Cr
1175.8+15.8 (1.36%)
1152.10
1185.70
1,16,658Cr
1398+3.5 (0.25%)
1364.50
1419
1,11,484Cr
2038.3+84.3 (4.31%)
1963.80
2055.30
1,09,943Cr
2483.4+182.7 (7.94%)
2303
2504.30
1,01,712Cr
1199.4+14.4 (1.22%)
1185
1222
1,01,005Cr
1726-8 (-0.46%)
1689.30
1740
99,253Cr
2096.2+13.2 (0.63%)
2080
2135
96,031Cr
670-11.75 (-1.72%)
665
694.95
1,608Cr

Accent Microcell Ltd Annual Results Key Takeaways

Basis: Consolidated annual results.

Accent Microcell Ltd Quaterly Results Key Takeaways